Overview
Betamethasone phosphate is a prodrug that is rapidly hydrolyzed, providing rapidly accessible betamethasone to agonize glucocorticoid receptors. Betamethasone provides greater anti-inflammatory activity than prednisolone with less sodium and water retention. Betamethasone sodium phosphate was granted FDA approval on 3 March 1965.
Indication
Betamethasone phosphate is indicated intramuscularly to treat allergic states, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system conditions, ophthalmic diseases, renal diseases, respiratory diseases, rheumatic disorders, trichinosis with neurologic or myocardial involvement, and tuberculous meningitis with subarachnoid block or impending block. It is also used intra-articularly in the treatment of acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, and synovitis of osteoarthritis. Intralesional betamethasone phospahte is indicated in the treatment of alopecia areata, discoid lupus erythematosus, keloids, lichen planus, lichen simplex chronicus, psoriatic plaques, necrobiosis lipoidica diabeticorum, and localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare.
Associated Conditions
- Acute Gouty Arthritis
- Allergic Conditions
- Alopecia Areata (AA)
- Dermatological Disease
- Discoid Lupus Erythematosus (DLE)
- Diseases of the Nervous System
- Endocrine Disorders
- Epicondylitis
- Gastrointestinal Diseases
- Hematologic Disease and Disorders
- Keloids Scars
- Kidney Diseases
- Lichen Planus (LP)
- Lichen simplex chronicus
- Necrobiosis lipoidica diabeticorum
- Neoplasm
- Ophthalmic Diseases
- Psoriatic plaque
- Respiratory Diseases
- Rheumatism
- Rheumatoid Arthritis
- Acute Bursitis
- Acute nonspecific tenosynovitis
- Cystic tumors of aponeurosis
- Cystic tumors of tendon
- Localized Hypertrophic, Inflammatory, Infiltrated granuloma annulare lesions
- Subacute Bursitis
- Synovitis of osteoarthritis
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|
No clinical trials found
No clinical trials found for this drug
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| QUADRICREM CREAM | N/A | N/A | N/A | 12/7/2009 | |
| BETNOVATE SCALP APPLICATION 0.1% | N/A | N/A | N/A | 6/12/1979 | |
| BETAGEN CREAM | N/A | N/A | N/A | 8/13/1982 | |
| BETNOVATE OINT 0.1% | N/A | N/A | N/A | 12/9/1978 | |
| SOLAIN CREAM | N/A | N/A | N/A | 11/3/2020 | |
| BETNOVATE CREAM 0.1% | N/A | N/A | N/A | 12/9/1978 | |
| QUADRIGEN CREAM | N/A | N/A | N/A | 11/12/1982 | |
| BETNOVATE-N CREAM | N/A | N/A | N/A | 12/9/1978 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.